Sunshine Biopharma Inc (SBFM) - Total Assets
Based on the latest financial reports, Sunshine Biopharma Inc (SBFM) holds total assets worth $31.49 Million USD as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See shareholders equity of Sunshine Biopharma Inc for net asset value and shareholders' equity analysis.
Sunshine Biopharma Inc - Total Assets Trend (2007–2024)
This chart illustrates how Sunshine Biopharma Inc's total assets have evolved over time, based on quarterly financial data.
Sunshine Biopharma Inc - Asset Composition Analysis
Current Asset Composition (December 2024)
Sunshine Biopharma Inc's total assets of $31.49 Million consist of 85.0% current assets and 15.0% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 31.7% |
| Accounts Receivable | $3.87 Million | 12.7% |
| Inventory | $11.28 Million | 36.9% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $3.02 Million | 9.9% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2007–2024)
This chart illustrates how Sunshine Biopharma Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see SBFM market cap.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Sunshine Biopharma Inc's current assets represent 85.0% of total assets in 2024, a decrease from 100.0% in 2007.
- Cash Position: Cash and equivalents constituted 31.7% of total assets in 2024, down from 100.0% in 2007.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 9.0% of total assets, an increase from 0.0% in 2007.
- Asset Diversification: The largest asset category is inventory at 36.9% of total assets.
Sunshine Biopharma Inc Competitors by Total Assets
Key competitors of Sunshine Biopharma Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Changchun High & New Technology Industries Group Inc
SHE:000661
|
China | CN¥31.46 Billion |
|
Yuhan Corp.
KO:000100
|
Korea | ₩3.05 Trillion |
|
Tasly Pharmaceutical Group Co Ltd
SHG:600535
|
China | CN¥15.34 Billion |
|
Zhejiang Hisun Pharmaceutical Co Ltd
SHG:600267
|
China | CN¥15.32 Billion |
|
Zhejiang Jiuzhou Pharm Co Ltd
SHG:603456
|
China | CN¥10.96 Billion |
|
Shanghai Yizhong Pharmaceutical Co Ltd
SHG:688091
|
China | CN¥1.54 Billion |
|
Jiangsu Kanion Pharmaceutical Co Ltd
SHG:600557
|
China | CN¥6.74 Billion |
|
Cronos Group Inc
TO:CRON
|
Canada | CA$1.18 Billion |
Sunshine Biopharma Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 4.20 | 5.74 | 0.98 |
| Quick Ratio | 2.09 | 3.57 | 0.95 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $21.32 Million | $21.45 Million | $-25.36K |
Sunshine Biopharma Inc - Advanced Valuation Insights
This section examines the relationship between Sunshine Biopharma Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.24 |
| Latest Market Cap to Assets Ratio | 0.17 |
| Asset Growth Rate (YoY) | 11.8% |
| Total Assets | $30.56 Million |
| Market Capitalization | $5.18 Million USD |
Valuation Analysis
Below Book Valuation: The market values Sunshine Biopharma Inc's assets below their book value (0.17x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: Sunshine Biopharma Inc's assets grew by 11.8% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Sunshine Biopharma Inc (2007–2024)
The table below shows the annual total assets of Sunshine Biopharma Inc from 2007 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $30.56 Million | +11.75% |
| 2023-12-31 | $27.35 Million | -7.44% |
| 2022-12-31 | $29.55 Million | +1241.20% |
| 2021-12-31 | $2.20 Million | +110.71% |
| 2020-12-31 | $1.05 Million | +965.27% |
| 2019-12-31 | $98.14K | -91.44% |
| 2018-12-31 | $1.15 Million | +345.30% |
| 2017-12-31 | $257.49K | +299.80% |
| 2016-12-31 | $64.40K | -90.43% |
| 2015-12-31 | $673.26K | +369.42% |
| 2014-12-31 | $143.42K | +359.10% |
| 2013-12-31 | $31.24K | -76.82% |
| 2012-12-31 | $134.79K | +26.64% |
| 2011-12-31 | $106.44K | -48.74% |
| 2010-12-31 | $207.62K | +85.19% |
| 2009-12-31 | $112.12K | +2129.39% |
| 2008-12-31 | $5.03K | -66.24% |
| 2007-12-31 | $14.89K | -- |
About Sunshine Biopharma Inc
Sunshine Biopharma, Inc. operates as a pharmaceutical company that focuses on the research and development of life-saving medicines in various therapeutic areas, including oncology and antivirals in the United States and Canada. It operates through Prescription Generic Pharmaceuticals and Nonprescription Over-The-Counter Products segments. The company is developing SBFM-PL4, a protease inhibitor … Read more